Literatur

1. Dimopoulos MA et al. Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma. N Engl J Med 2016; 375: 1319-31.
2. Dimopoulos MA et al. ASH 2017, Abstract #739.
3. Lentzsch S et al. ASH 2017, Abstract #1852.
4. Usmani SZ et al. ASH 2016, Abstract #1149.
5. Chari A et al. ASH 2017, Abstract #838.
6. Dimopoulos MA et al. ASH 2017, Abstract #902.
7. ClinicalTrials.gov No. NCT02181413.
8. ClinicalTrials.gov No. 02312258.
9. ClinicalTrials.gov No. 01850524.
10. Thomas SK et al. ASH 2017, Abstract #840.
11. Attal M et al. Lenalidomide, Bortezomib, and Dexamethasone with Transplantation for Myeloma. N Engl J Med 2017; 376: 1311-20.
12. Gardaret L et al. ASH 2017, Abstract #837.
13. San Miguel JF et al. Persistent overall survival benefit and no increased risk of second malignancies with bortezomib-melphalan-prednisone versus melphalan-prednisone in patients with previously untreated multiple myeloma. J Clin Oncol 2013; 31: 448-55.
14. Mateos MV et al. ASH 2017, Abstract #LBA-4.
15. Mateos MV et al. Haematologica 2015; 100 (Suppl 1): EHA 2015, Abstract #275.
16. Kyle R et al. Clinical course and prognosis of smoldering (asymptomatic) multiple myeloma. N Engl J Med 2007; 356: 2582-90.
17. Mateos MV et al. Lenalidomide plus dexamethasone versus observation in patients with high-risk smouldering multiple myeloma (QuiRedex): Long-term follow-up of a randomised, controlled, phase 3 trial. Lancet Oncol 2016; 17: 1127-36.
18. Mateos MV et al. ASH 2017, Abstract #402.
19. Cohen AD et al. ASH 2017, Abstract #505.
20. Yan L et al. ASH 2017, Abstract #506.
21. Berdeja JG et al. ASH 2017, Abstract #740.
22. ClinicalTrials.gov No. 03361748.
23. Trudel S et al. ASH 2017, Abstract #741.